Souhaitez-vous accéder aux communiqués récents ?

The registrational intent ACR-368 Phase 2b study is advancing with a prespecified simultaneous interim analysis and data update for both all-comer (biopsy-independent) serous endometrial cancer arms...

Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights

Longeveron (LGVN), developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, reported 1Q26 financial results.

Issued on behalf of Western Star Resources Inc. A CMETC-eligible flow-through financing, a €200,000 European IR mandate, and a DIBC application land in the same week — under eight months before the...

Issued on behalf of NevGold Corp. The U.S. critical minerals reset is no longer theoretical — it’s a national security scramble after China restricted antimony exports for U.S. military end use,...

Revenue grew approximately 35% year-over-year to $15.5 million for Q1 2026 Net income increased by over 100% year-over-year to $2.3 million for Q1 2026 Adjusted EBITDA for Q1 of 2026 more than...

C-BEYOND Phase 3 North American Trial for Treatment of Hepatitis C Virus (HCV) Remains on Track with Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial Outside North America for Treatment of...

– Contract Research Organization for the Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Informed the Company that 78 Events have Occurred in the Trial as of May...

– $5.8 million in KOMZIFTI™ (ziftomenib) net product revenue in first full quarter of commercialization – – Robust new patient starts and early launch dynamics, including repeat use, switching and...

CBeyond™ Expansion Study (Part C) initiated; Cohort Review Committee review scheduled for May 18, 2026, to evaluate available safety data and potential progression to Cohort 2 SAN DIEGO, May 12,...